Rhythm Pharmaceuticals (RYTM) Stock Forecast, Price & News

Rhythm Pharmaceuticals (NASDAQ:RYTM) Frequently Asked Questions

Is Rhythm Pharmaceuticals a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rhythm Pharmaceuticals in the last year. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Rhythm Pharmaceuticals stock.
View analyst ratings for Rhythm Pharmaceuticals or view top-rated stocks.

When is Rhythm Pharmaceuticals' next earnings date?

Rhythm Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for Rhythm Pharmaceuticals.

How were Rhythm Pharmaceuticals' earnings last quarter?

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) issued its quarterly earnings data on Tuesday, May, 3rd. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.98) by $0.07. Rhythm Pharmaceuticals had a negative trailing twelve-month return on equity of 55.66% and a negative net margin of 3,598.16%. During the same period in the previous year, the business earned $0.90 EPS.
View Rhythm Pharmaceuticals' earnings history.

What price target have analysts set for RYTM?

8 analysts have issued 1-year price objectives for Rhythm Pharmaceuticals' shares. Their forecasts range from $9.00 to $45.00. On average, they expect Rhythm Pharmaceuticals' share price to reach $25.38 in the next year. This suggests a possible upside of 676.0% from the stock's current price.
View analysts' price targets for Rhythm Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Rhythm Pharmaceuticals' key executives?

Rhythm Pharmaceuticals' management team includes the following people:

• Dr. David P. Meeker M.D., Chairman, Pres & CEO (Age 68, Pay $836.08k)
• Mr. Hunter C. Smith M.B.A., CFO & Treasurer (Age 53, Pay $692.84k)
• Ms. Jennifer L. Chien, Exec. VP & Head of North America (Age 47, Pay $194.95k)
• Mr. William T. Roberts, Chief Accounting Officer (Age 43)
• Mr. Joseph Shulman, Chief Technical Officer
• Mr. David Connolly, Head of Investor Relations & Corp. Communications
• Mr. Jim Flaherty, Sr. VP & Gen. Counsel
• Ms. Sarah Ryan, VP of Sales & Marketing
• Ms. Pamela Cramer, Chief HR Officer
• Mr. Yann Mazabraud, Exec. VP & Head of International (Age 49)

What is 's approval rating as Rhythm Pharmaceuticals' CEO?

1 employees have rated Rhythm Pharmaceuticals CEO on Glassdoor.com. has an approval rating of 100% among Rhythm Pharmaceuticals' employees. This puts in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Rhythm Pharmaceuticals' key competitors?

Some companies that are related to Rhythm Pharmaceuticals include Verve Therapeutics (VERV), PMV Pharmaceuticals (PMVP), Avidity Biosciences (RNA), Atai Life Sciences (ATAI), uniQure (QURE), Design Therapeutics (DSGN), Atea Pharmaceuticals (AVIR), Relmada Therapeutics (RLMD), Kiniksa Pharmaceuticals (KNSA), Eagle Pharmaceuticals (EGRX), AnaptysBio (ANAB), POINT Biopharma Global (PNT), Gossamer Bio (GOSS), Amarin (AMRN) and Foghorn Therapeutics (FHTX).
View all of RYTM's competitors.

What other stocks do shareholders of Rhythm Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rhythm Pharmaceuticals investors own include VBI Vaccines (VBIV), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Viking Therapeutics (VKTX), Amarin (AMRN), Kadmon (KDMN), Pfizer (PFE), Sangamo Therapeutics (SGMO) and Sarepta Therapeutics (SRPT).

When did Rhythm Pharmaceuticals IPO?

(RYTM) raised $100 million in an IPO on Thursday, October 5th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen served as the underwriters for the IPO and Needham was co-manager.

What is Rhythm Pharmaceuticals' stock symbol?

Rhythm Pharmaceuticals trades on the NASDAQ under the ticker symbol "RYTM."

Who are Rhythm Pharmaceuticals' major shareholders?

Rhythm Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Primecap Management Co. CA (12.49%), Federated Hermes Inc. (10.05%), Goldman Sachs Group Inc. (6.63%), BlackRock Inc. (6.52%), Vanguard Group Inc. (4.48%) and Rock Springs Capital Management LP (2.45%). Company insiders that own Rhythm Pharmaceuticals stock include David P Meeker, Hunter C Smith, Joseph Shulman, Nithya Desikan, Ra Capital Management, LP, Todd Foley, William T Roberts and Yann Mazabraud.
View institutional ownership trends for Rhythm Pharmaceuticals.

Which major investors are selling Rhythm Pharmaceuticals stock?

RYTM stock was sold by a variety of institutional investors in the last quarter, including Deerfield Management Company L.P. Series C, State Street Corp, Wellington Management Group LLP, Endurant Capital Management LP, Citigroup Inc., Vanguard Group Inc., BlackRock Inc., and BNP Paribas Arbitrage SA. Company insiders that have sold Rhythm Pharmaceuticals company stock in the last year include Hunter C Smith, Joseph Shulman, William T Roberts, and Yann Mazabraud.
View insider buying and selling activity for Rhythm Pharmaceuticals or view top insider-selling stocks.

Which major investors are buying Rhythm Pharmaceuticals stock?

RYTM stock was acquired by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Rock Springs Capital Management LP, Goldman Sachs Group Inc., Pinz Capital Management LP, Bell & Brown Wealth Advisors LLC, Primecap Management Co. CA, Dimensional Fund Advisors LP, and Renaissance Technologies LLC.
View insider buying and selling activity for Rhythm Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Rhythm Pharmaceuticals?

Shares of RYTM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rhythm Pharmaceuticals' stock price today?

One share of RYTM stock can currently be purchased for approximately $3.27.

How much money does Rhythm Pharmaceuticals make?

Rhythm Pharmaceuticals has a market capitalization of $164.79 million and generates $3.15 million in revenue each year. The company earns $-69.61 million in net income (profit) each year or ($3.30) on an earnings per share basis.

How many employees does Rhythm Pharmaceuticals have?

Rhythm Pharmaceuticals employs 140 workers across the globe.

What is Rhythm Pharmaceuticals' official website?

The official website for Rhythm Pharmaceuticals is www.rhythmtx.com.

How can I contact Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals' mailing address is 222 BERKELEY STREET 12TH FLOOR, BOSTON MA, 02116. The company can be reached via phone at (857) 264-4280, via email at [email protected], or via fax at 857-264-4299.